BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to “Sell”

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Thursday.

A number of other equities research analysts have also recently issued reports on ICPT. Wedbush reiterated a “buy” rating and set a $253.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. Credit Suisse Group set a $167.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 22nd. JMP Securities cut shares of Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 4th. Leerink Swann reiterated a “hold” rating and set a $60.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, November 28th. Finally, ValuEngine upgraded shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $134.86.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $64.92 on Thursday. The company has a market cap of $1,630.00, a PE ratio of -4.39 and a beta of -2.05. Intercept Pharmaceuticals has a 1-year low of $51.53 and a 1-year high of $135.59. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The firm’s revenue for the quarter was up 697.9% compared to the same quarter last year. During the same period last year, the firm earned ($3.59) EPS. research analysts anticipate that Intercept Pharmaceuticals will post -13.36 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. WFG Advisors LP increased its position in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares in the last quarter. IFP Advisors Inc increased its position in Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,182 shares in the last quarter. QCM Cayman Ltd. acquired a new stake in Intercept Pharmaceuticals in the 2nd quarter valued at about $237,000. Birchview Capital LP acquired a new stake in Intercept Pharmaceuticals in the 3rd quarter valued at about $250,000. Finally, Oppenheimer & Co. Inc. increased its position in Intercept Pharmaceuticals by 145.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 2,833 shares in the last quarter. Hedge funds and other institutional investors own 73.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/28/bidaskclub-upgrades-intercept-pharmaceuticals-icpt-to-sell.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply